Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer ...

Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

A large CT imaging study identifies many clues which are the key risk factors linked to fast-growing lung cancer, supporting ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...

The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...

It’s the third most common cancer in the UK, causing tens of thousands of deaths annually. But what if the disease, often only diagnosed when it’s too late, could be stopped before it even begins?

The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...

Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...

There are many serious health conditions and diseases that are associated with aging, like pneumonia, as well as lung cancer ...